OEM Enanthate - Other Protected Amino Acids for Disulfide bond – Gentolex
OEM Enanthate - Other Protected Amino Acids for Disulfide bond – Gentolex Detail:
Product Detail
|
NO |
Products |
CAS No |
Application |
Key Quality Indicator |
||||
|
Purity |
Isomer |
Specific impurity |
*Max1 |
Moisture |
||||
|
1 |
Fmoc-Cys(Acm)-OH |
86060-81-3 |
Disulfide bond |
≥99.0% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
2 |
Fmoc-Cys(Mmt)-OH |
177582-21-7 |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
3 |
Fmoc-Cys(4-allylbutyrate)-OH |
/ |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
4 |
Mpa(Trt)-OH |
27144-18-9 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
5 |
Fmoc-Thr(tBu)-OL |
189337-28-8 |
Octreotide |
≥97.0% |
≤0.3% |
≤0.5% |
≤1.0% |
≤1.0% |
|
6 |
Fmoc-D-Arg(pbf)-OH |
187618-60-6 |
Desmopressin |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤2.0% |
|
7 |
Fmoc-Gly-Gly-OH |
35665-38-4 |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
8 |
Fmoc-Gly-Gly-Gly-OH |
170941-79-4 |
Terlipressin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
9 |
Fmoc-Gly-Gly-Gly-Gly-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
10 |
Fmoc-Gly-Asp(tBu)-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.15% |
≤0.2% |
≤1.0% |
|
11 |
Boc-Cys(Trt)-OH |
21947-98-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
12 |
Boc-Arg(pbf)-OH |
200124-22-7 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
13 |
Boc-Ala-OH |
15761-38-3 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
14 |
Boc-D-Phe-OH |
18942-49-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
15 |
Boc-Gly-OH |
4530-20-5 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
16 |
Boc-Lys(Boc)-OH.DCHA |
15098-69-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
17 |
Boc-Ser(tBu)-OH |
7738-22-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
18 |
Boc-Thr(tBu)-OH |
13734-40-2 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
19 |
Boc-D-Ala-OH |
7764-95-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
20 |
Boc-Met-OH |
2488-15-5 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
21 |
Boc-Tyr(tBu)-OH |
47375-34-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
22 |
Boc-D-Arg(pdf)-OH |
187618-60-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
23 |
Boc-Asp(OtBu)-OH.DCHA |
1913/12/8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
24 |
Fmoc-HomoArg(pbf)-OH |
1159680-21-3 |
Eptifibatide |
≥98.5% |
≤0.2% |
/ |
≤0.5% |
≤2.0% |
|
25 |
Fmoc-Asp-OtBu |
129460-09-9 |
Thymalfasin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
26 |
Fmoc-Tyr(Me)-OH |
77128-72-4 |
Carbetocin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
27 |
Fmoc-Orn(Boc)-OH |
109425-55-0 |
Atosiban Omnipressin Daptomycin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤2.0% |
|
28 |
Fmoc-D-Tyr(Et)-OH |
162502-65-0 |
Atosiban |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
29 |
Fmoc-Asp(OAll)-OH |
146982-24-3 |
Melanotan |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
30 |
Ac-Nle-OH |
15891-49-3 |
Melanotan |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
31 |
Fmoc-Nle-OH |
77284-32-3 |
Melanotan Afamelanotide |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
32 |
Ac-Glu(OtBu)-OH |
84192-88-1 |
Argireline Acetyl octapeptide-3 |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
33 |
Ac-β-Ala-OH·DCHA |
/ |
Acetyl tetrapeptide-5 |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
34 |
Fmoc-ß-Ala-OH |
35737-10-1 |
Acetyl tetrapeptide-5 |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
35 |
Fmoc-Hyp(tBu)-OH |
122996-47-8 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
36 |
Fmoc-Thi-OH |
130309-35-2 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
37 |
Fmoc-D-Tic-OH |
130309-33-0 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
38 |
Fmoc-Oic-OH |
130309-37-4 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
39 |
Boc-Sar-OH |
13734-36-6 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
40 |
Fmoc-Sar-OH |
77128-70-2 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
41 |
Fmoc-Tyr(SO3Na)-OH.H2O |
106864-37-3 |
Sincalide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
42 |
Fmoc-D-Asp(OtBu)-OH |
112883-39-3 |
Daptomycin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
43 |
Ac-Ser(tBu)-OH |
77285-09-7 |
Afamelanotide |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
44 |
Boc-HomoCys(Trt)-OH |
201419-16-1 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
45 |
Fmoc-HomoCys(Trt)-OH |
167015-23-8 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
46 |
Fmoc-Dab-OH |
161420-87-7 |
Snake venom |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
*Max1 = Max Unknown Purity
Other Indicator:
- Acetic Acid: ≤0.02% (All Products)
- Ethyl Acetate: ≤0.5% (All Products)
- Alcohol: ≤0.5% (All Products)
- Max Unknow Impurity: Fmoc-Trp(Boc)-OH (143824-78-6) ≤0.3%; Others ≤0.2%
Product detail pictures:
Related Product Guide:
The key to our success is "Good Product or service High quality, Reasonable Rate and Efficient Service" for OEM Enanthate - Other Protected Amino Acids for Disulfide bond – Gentolex , The product will supply to all over the world, such as: Kuwait, Senegal, Peru, Our company abides by the management idea of "keep innovation, pursue excellence". On the basis of assuring the advantages of existing merchandise, we continuously strengthen and extend product development. Our company insists on innovation to promote the sustainable development of enterprise, and make us become the domestic high-quality suppliers.
By Marguerite from Belarus - 2017.06.16 18:23
With a positive attitude of "regard the market, regard the custom, regard the science", the company works actively to do research and development. Hope we have a future business relationships and achieving mutual success.
By Samantha from Argentina - 2017.06.22 12:49
